Recent News
Pleural Mesothelioma and Brain Metastasis
When people are diagnosed with mesothelioma, it is common for the disease to spread. This occurs in around 60 percent of people, but it does not usually spread to the…
Enzyme and Chemotherapy Combination for Mesothelioma
Pleural mesothelioma sufferers could improve their survival by as much as 30 percent when treated with the latest cancer enzyme and chemotherapy. In a recent study known as ATOMIC Meso,…
A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Primary Outcome Measures Number of participants with adverse events (AEs) [ Time Frame: Through 30 days after the last study treatment; approximately 7 months ] Any untoward medical occurrence in a clinical investigational participant…
STAR-101 Could Make CAR T-Cell Therapy More Effective for Mesothelioma Patients
Early next year, a new clinical trial will be conducted to test an immunotherapy treatment that has a new and unique delivery system. The study will be conducted at the…
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Primary Outcome Measures Safety and feasibility of SynKIR-110 [ Time Frame: Date of enrollment through date of last patient visit, up to 36 months. ] • The incidence, frequency, and severity of TEAEs, incidence…
CARD is Performing Asbestos Screenings Throughout Montana
Asbestos exposure screenings are being performed in Libby, Montana. The Center for Asbestos Related Disease (CARD) is going around the state offering screenings to people who cannot or are not…
A Phase 1 Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Primary Outcome Measures Dose limiting toxicity (DLT) of PRT3645 [ Time Frame: Baseline through Day 28 ] Dose limiting toxicity will be evaluated over the 28-day observation period Safety and tolerability of PRT3645: AEs,…
A Protein Could Make Chemotherapy More Effective on Mesothelioma
Mesothelioma is a rare cancer with a poor life expectancy. People diagnosed with pleural mesothelioma usually live for four to 18 months after diagnosis. The poor survival is a result…
Mesothelioma Specialty Centers Offer Better Care for Mesothelioma Patients
When mesothelioma patients are treated at mesothelioma specialty centers, they experience better care and survive longer. Kaiser Permanente Northern California Health System compared its performance before and after it transitioned…
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study (TIGER Meso)
Primary Outcome Measures Time from diagnosis of pleural mesothelioma to death of any cause as median overall survival time. [ Time Frame: 54 Months ] Secondary Outcome Measures Number of TTFields treatment-related SAEs, as…
